Evidence map›Paper›PMID 36189777›Full record

ArticleAddiction (Abingdon, England)2023

Association of cannabis use during pregnancy with severe acute respiratory syndrome coronavirus 2 infection: a retrospective cohort study.

Kelly C Young-Wolff, G Thomas Ray, Stacey E Alexeeff, Neal Benowitz, Sara R Adams, Monique B Does, Nancy Goler, Deborah Ansley, Amy Conway, Lyndsay A Avalos

Open access · hybridAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Acute Toxicity and Pharmacokinetic Profile of an EU-GMP-CertifiedPharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.ORCID 0000-0002-6177-534X
G Thomas RayDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Neal BenowitzResearch Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine and Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2041-8124
Sara R AdamsDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Monique B DoesDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Nancy GolerRegional Offices, Kaiser Permanente Northern California, Oakland, CA, USA.
Deborah AnsleyRegional Offices, Kaiser Permanente Northern California, Oakland, CA, USA.
Amy ConwayRegional Offices, Kaiser Permanente Northern California, Oakland, CA, USA.
Lyndsay A AvalosDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Kaiser Permanente · USUniversity of California, San Francisco · US

Funding

Maternal Marijuana Use During Pregnancy, Marijuana Legalization, and Adverse Obstetrical and Neonatal Outcomes: A 12-year Cohort StudyR01DA047405 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI AVALOS, LYNDSAY AMMON, YOUNG-WOLFF, KELLY CORINNE · 2019 to 2023
$3.5M
Impact of in utero Marijuana Exposure on Neurodevelopment, Behavior and Mental Health: A Longitudinal Birth Cohort StudyR01DA048033 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI AVALOS, LYNDSAY AMMON, YOUNG-WOLFF, KELLY CORINNE · 2020 to 2025
$3.1M
Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NIDA NIH HHS K01 DA043604NIDA NIH HHS R01 DA047405NIDA NIH HHS R01 DA048033
6 · The paper itself

Abstract

BACKGROUND AND

aimsCannabis use is increasingly common among pregnant individuals and might be a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to test whether prenatal cannabis use is associated with increased risk of SARS-CoV-2 infection during pregnancy.

designThis is a retrospective cohort study.

settingThe study was conducted in California, USA.

participantsA total of 58 114 pregnancies (with outcomes from 5 March 2020 to 30 September 2021) among 57 287 unique pregnant women aged 14-54 years who were screened for prenatal substance use, enrolled in Kaiser Permanente Northern California (KPNC) (a health-care system) and had not tested positive for COVID-19 prior to pregnancy onset. MEASUREMENTS: We utilized data from the KPNC electronic health record. Cannabis use status (current, recently quit and non-user) was based on universal screenings during prenatal care (including urine toxicology testing and self-reported use on a self-administered questionnaire). SARS-CoV-2 infection [based on polymerase chain reaction (PCR) tests] was estimated in time-to-event analyses using Cox proportional hazard regression models adjusting for covariates. Secondary analyses examined differences in (a) SARS-CoV-2 testing rates and (b) SARS-CoV-2 infection rates among those tested.

findingsWe observed 348 810 person-months of follow-up time in our cohort with 41 064 SARS-CoV-2 PCR tests and 6% (n = 2414) of tests being positive. At the start of follow-up, 7% of pregnant individuals had current use, 12% had recently quit and 81% did not use cannabis. Adjusting for covariates, current use was associated with lower rates of SARS-CoV-2 infection [adjusted hazard ratio (aHR) = 0.60, 95% confidence interval (CI) = 0.49-0.74 than non-use. Those who had recently quit did not differ from non-cannabis users in infection rates (aHR = 0.96, 95% CI = 0.86-1.08). Sensitivity analyses among patients who received a SARS-CoV-2 test also found lower odds of infection associated with current versus no cannabis use (aOR = 0.76, CI = 0.61-0.93).

conclusionsCurrent cannabis use appears to be associated with a reduced risk of SARS-CoV-2 infection among pregnant individuals.

Indexed as

CannabisCOVID-19Pregnancy Complications, InfectiousCOVID-19 TestingFemaleHumansPregnancyRetrospective StudiesSARS-CoV-2CannabisCOVID-19marijuanapregnancyprenatalSARS-CoV-2

Identifiers

PMID36189777
PMCPMC9812868
OpenAlexW4300689169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.